Monkey pox B04.x0

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 25.09.2022

Dieser Artikel auf Deutsch

Synonym(s)

Human monkeypox; Human monkeypox virus infection

History
This section has been translated automatically.

Since monkeypox was first diagnosed in humans in the Democratic Republic of Congo (DRC) in 1970, it has spread to other regions of Africa (primarily West and Central Africa). Since 2003, importation- and travel-related spread outside of Africa has resulted in occasional outbreaks. Interactions/activities with infected animals or individuals are risk behaviors associated with monkeypox acquisition. Recent research shows an escalation of monkeypox cases, particularly in the highly endemic Democratic Republic of Congo, spread to other countries, and an increase in median age from young children to young adults. According to the RKI, the increase in infections observed in Germany in 2022 primarily affected men who have sex with men (RKI 2022 communication).

Definition
This section has been translated automatically.

Formerly sporadic in rural areas of the tropical rainforest (Cameroon, Liberia, Nigeria, Sierra Leone, Gabon, Democratic Republic of Congo, Côte d'Ivoire, Central African Republic), zoonotic infection caused by an orthopoxvirus leading to a pox-like disease in humans.

Pathogen
This section has been translated automatically.

orthopox virus, which has undergone an evolution independent of the variola virus.

Occurrence/Epidemiology
This section has been translated automatically.

Transmission is by direct contact or aerosol. 28% human-to-human transmission (the chain of infection breaks quickly), otherwise through contact with sick animals. Approximately 65 reported infections annually. 30% of infections are subclinical. Lethal outcome possible. Presumed protection by smallpox vaccination. In 2022, increased incidence of infection was observed in men with homosexual contact.

By 8/25/2022, the percentage of reported monkeypox cases was distributed as follows:

  • 52 percent (24,172 cases in 29 countries and territories) reported in the WHO Americas region.
  • 46 percent (21,246 cases in 43 countries) in the WHO European Region
  • <1 percent (445 cases in 9 countries) in the WHO African Region
  • < 1 percent (135 cases in 8 countries) in the WHO Western Pacific Region
  • <1 percent (36 cases in 7 countries) in the WHO Eastern Mediterranean Region
  • < 1 percent (14 cases in 3 countries) in the WHO South-East Asia Region

Manifestation
This section has been translated automatically.

Of the confirmed cases with known information (n=22,154), 98.2% (21,757) are male.

The average age is 36 years.

Regarding sexual orientation, of the 10,785 cases with available information, 96% of males reported same-sex sexual contact (MSM). Of the 10,963 cases with available information on HIV infection, 44 percent were HIV-positive.

Clinical features
This section has been translated automatically.

The clinical picture is similar to variola infection. Incubation period is about 12 days. The clinical picture begins with fever, a patchy exanthema, severe headache and back pain, and a severe feeling of illness. Almost simultaneously, there is an outbreak of typical smallpox exanthema. Papules become pustules with typical central indentation. A high percentage of patients also develop mucosal involvement. The disease lasts 2-4 weeks. The efflorescences heal with scarring. After the efflorescences have completely dried up, the lesions are no longer contagious.

Diagnostics
This section has been translated automatically.

Monkeypox can be confirmed by polymerase chain reaction (PCR) (lesional smear) or immunohistochemistry. Pustule contents with electron microscopic evidence of the 300x200nm monkeypox virus. A skin biopsy of the vesiculopustular rash or from the roof of an intact vesiculopustule can be analyzed for this purpose.

A Tzanck smear can be helpful in distinguishing monkeypox from other non-viral diseases, but not from smallpox or herpes infections.

Laboratory
This section has been translated automatically.

CBC, CRP, ESR, liver and kidney function. Of importance would be testing for syphilis, HIV or other STDs, especially in MSM patients.

Complication(s)
This section has been translated automatically.

Risk of scarring. Secondary bacterial infections may occur.

Mortality in Africa ranges from 1% to 10.6% in high-risk individuals (e.g., immunocompromised, malnourished).

General therapy
This section has been translated automatically.

In immunocompetent patients, the disease is usually self-limiting after 2-4 weeks. Isolation of the patient is necessary, symptomatic and supportive measures (e.g. analgesia, topical antiseptic therapy- prevention of bact. superinfection). Disinfection of surfaces and objects, appropriate washing for textiles.
Examination of partners. Vaccinations are available after risk exposure.
Special attention to HIV, immunosuppressed and malnourished patients. Currently, there is no specific treatment approved for monkeypox virus infections. However, antivirals developed for use in patients with smallpox may prove beneficial. The following medical countermeasures are currently available.

  • Tecovirimat (also known as TPOXX) is an antiviral drug approved by the United States Food and Drug Administration (FDA).
  • Cidofovir (also known as Vistide) is an antiviral drug approved by the FDA.
  • Brincidofovir (also known as Tembexa) is an antiviral drug approved by the FDA on June 4, 2021, for the treatment of human smallpox disease in adult and pediatric patients, including newborns. Centers for Disease Control and Prevention (CDC) is currently developing an EA-IND to facilitate the use of brincidofovir for the treatment of monkeypox.

Progression/forecast
This section has been translated automatically.

The overall mortality rate was 8.7%, with a significant difference between the regional collectives:

  • Central Africa 10.6% (95% CI: 8.4% - 13.3%) vs.
  • West Africa 3.6% (95% CI: 1.7% - 6.8%).

Prophylaxis
This section has been translated automatically.

The live vaccine (Imvanex®, 3rd generation) is available for the prophylaxis of monkeypox. Imvanex® has been approved by the EMA for the prophylaxis of smallpox since 2013, and the indication has been expanded in 2022 following increased occurrences of monkeypox in Europe. Full vaccine protection is present after two administrations (at least 28 days apart).

Postexposure prophylaxis: Vaccination with Imvanex® should be offered after high-risk contact with close physical contact. In particular, this should be offered to patients with a severe course (e.g. HIV-infected patients).

Note(s)
This section has been translated automatically.

For monkeypox virus, there is both a medical notification requirement and a laboratory notification requirement under the Infection Protection Act (IfSG).

Literature
This section has been translated automatically.

  1. Bunge EM et al. (2022) The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis 16:e0010141.
  2. Mukinda VB et al (1997) Re-emergence of human monkeypox in Zaire in 1996. monkeypox Epidemiologic Working Group. Lancet 349: 1449-50
  3. Mukinda VB et al. (1997) Re-emergence of human monkeypox in Zaire in 1996. dermatologist 48:598.
  4. Meyer H et al. (2002) Outbreaks of disease suspected of being due to human monkeypox virus infection in the democratic republic of congo in 2001. J Clin Microbiol 40: 2919-2921.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 25.09.2022